[1] |
ZHANG Yu, ZHANG Wei, GAO Shuangrong, CHEN Mengping, WANG Yaxin, XU Yingli, CAO Shan, ZHAO Ronghua, BAO Lei, LI Shuran, SUN Jing, BAO Yanyan, GENG Zihan, GUO Shanshan, JI Zuen, CUI Xiaolan.
Screening and analysis of host factors interacting with NS1 proteins of influenza A virus based on the proteome chip
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 40-44.
|
[2] |
YANG Zhenzhen, CHANG Cheng, GAO Na, ZHANG Xiaolin, SONG Yinsen, LIU Ying, FAN Tianli.
Molecular mechanism of luteolin for inhibiting esophageal squamous cell carcinoma based on network pharmacology and in vitro studies
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 992-1001.
|
[3] |
MEI Yu, ZHU Yue, ZHANG Huiting, XIAO Chengrong, GAO Yue, MA Zengchun.
Protective mechanism of Chinese medicine compound CB001 against low dose radiation based on network pharmacology and experimental verification
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 872-879.
|
[4] |
YU Ji, RAN Shuo.
Evaluation of drug use during applications of clinical pathways in patients with STEMI based on DUR and DUE
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 674-679.
|
[5] |
LIANG Jiaqi, SHAO Rong, LIU Pengcheng, LI Ming, RENG Jingtian, TANG Ren, WANG Yue.
Characteristics of dear health care provider letters in Europe and America
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 275-278.
|
[6] |
ZHANG Dan, LYU Jintao, SONG Haibo, ZHANG Bing, JIN Yongnan, SA Rina, ZHANG Xiaomeng, LIN Zhijian.
Drug Risk Communication among Drug Regulatory Agencies in the European Union, the United States and Asia
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 845-849.
|
[7] |
WANG Xiaoyan, LI Weixia, ZHANG Hui, ZHANG Mingliang, WU Yali, CAO Zhanxia, NI Wenjuan, CHEN Yulong, LI Kun, FENG Keran, TANG Jinfa.
The Mechanism of Psoralea Fructus Induced Idiosyncratic Liver Injury Based on Metabolomics
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1014-1019.
|
[8] |
HOU Yongfang, LIU hongliang, QI Yan.
An Overview of EudraVigilance and Implications for China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1058-1061.
|
[9] |
WEI Fuqian, ZHANG Wei, YANG Yue.
Drug Risk Communication between Drug Regulatory Agencies and the Public
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 949-952.
|
[10] |
WANG Yanchun, WANG Jianqiang.
Research Progress in Clinical Application of Shuganning Injection
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 543-547.
|
[11] |
LI Sizheng, HU Guang, HE Jingcheng, HU Yuchi, LI Zhiyong, JIN Hongtao.
The Role of Renin-angiotensin System in COVID-19 and Drug Intervention
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 267-271.
|
[12] |
WU Shifu, JIN Yi, CHANG Hong, TIAN Yuejie, XU Kui, XU Lili, GUO Fanling, ZHANG Jingdong.
Drug Risk Communication in the European Union and United States between Regulators and the Public
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 87-92.
|
[13] |
CUI Yuan, LI Haishan, SONG Naining, LI Bin, SUI Feng, LI Yingfei, GUO Jiabin, JIA Qiang, LI Hua, GAO Yue, SHEN Guolin.
Metabonomics Reveals that Aristolochic Acid I Affects β-oxidation of Fatty Acids, Glucose Metabolism and the TCA Cycle in the Mice Liver
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 449-466.
|
[14] |
QIU Caixia, YANG Cuiping, JIN Hongtao.
Research Progress in Mechanisms of Drug-induced Kidney Injury
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 688-694.
|
[15] |
YANG Jingjng, FENG Jie,ZHAO Sida,XU Ning,GAO Hua.
Effects of ERK1/2 Pathway Inhibitor U0126 on Cell Proliferation of Growth Homone Adenoma GH3 Cells
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(9): 530-532.
|